Company overview
Seer Inc. offers the Proteograph product suite, an integrated platform for deep, unbiased plasma proteomics using proprietary engineered nanoparticles, automation instruments, and analysis software. It enables large-scale proteomic profiling for biomarker discovery in areas like cancer, neurodegenerative, and metabolic diseases. The technology complements mass spectrometry systems, with a co-marketing agreement with Thermo Fisher Scientific for integration with Orbitrap Astral mass spectrometers.
Seer Inc. is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include seer proteograph, plasma proteomics, proteomic platform, nanoparticle proteomics, biomarker discovery.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://seer.bio/
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- seer proteograph, plasma proteomics, proteomic platform, nanoparticle proteomics, biomarker discovery
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are the core capabilities of Seer's Proteograph platform?
- The Proteograph suite provides deep, unbiased proteomic profiling of plasma and serum at scale, using engineered nanoparticles to access the full proteome dynamic range, combined with automation and analysis software for biomarker discovery.
- What is the regulatory status of Seer's products?
- Proteograph is designated for research use only (RUO), though Seer has secured certifications to advance toward clinical testing applications.
- What geographies does Seer serve and are there key partnerships?
- Seer operates globally, with Thermo Fisher Scientific's worldwide sales force promoting Proteograph via a co-marketing agreement starting early 2025; it integrates with systems like Orbitrap Astral and Bruker timsTOF.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
